Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1991-11-8
|
pubmed:abstractText |
The autoradiographic distribution, disposition, biliary excretion, and pharmacokinetics of alpidem in Sprague-Dawley rats were evaluated after iv or oral administration. Following i.v. administration, autoradiography showed that radioactivity was preferentially localized in lipid-rich tissues including central nervous system structures. After a 3-mg.kg-1 i.v. or oral dose of [14C]alpidem, more than 80% of the radioactivity were excreted in the feces over a 6-day period. Biliary excretion of radioactivity in vigile rats, about 74% of the dose over a 7-hr period after either iv or oral administration, showed that alpidem was well absorbed. The absolute bioavailability (13%) data indicated a high first-pass effect. Plasma pharmacokinetic parameters of alpidem were as follows: Vd = 5 liter.kg-1, Cl = 2.2 liter.h-1.kg-1, and terminal t 1/2 beta = 1.2-1.7 hr. Three metabolites with a pharmacological activity similar to that of alpidem were detected in plasma. They were eliminated from the central compartment with half-lives comparable to that of the parent drug. Alpidem crossed the blood-brain barrier following either i.v. or oral administration, resulting in cerebral levels 2.5 to 4 times greater than the plasma levels. Alpidem was eliminated from the central nervous system according a biphasic process with a t 1/2 alpha comparable in plasma and brain. Alpidem represented 94 and 63% of cerebral radioactivity 5 min after i.v. and oral administration, respectively. Two out of the three active plasma metabolites were detected in the brain.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0090-9556
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
574-9
|
pubmed:dateRevised |
2003-11-14
|
pubmed:meshHeading |
pubmed-meshheading:1680622-Administration, Oral,
pubmed-meshheading:1680622-Animals,
pubmed-meshheading:1680622-Anti-Anxiety Agents,
pubmed-meshheading:1680622-Autoradiography,
pubmed-meshheading:1680622-Bile,
pubmed-meshheading:1680622-Biotransformation,
pubmed-meshheading:1680622-Brain,
pubmed-meshheading:1680622-Chromatography, High Pressure Liquid,
pubmed-meshheading:1680622-Half-Life,
pubmed-meshheading:1680622-Imidazoles,
pubmed-meshheading:1680622-Injections, Intraventricular,
pubmed-meshheading:1680622-Male,
pubmed-meshheading:1680622-Pyridines,
pubmed-meshheading:1680622-Rats,
pubmed-meshheading:1680622-Rats, Inbred Strains,
pubmed-meshheading:1680622-Spectrometry, Fluorescence,
pubmed-meshheading:1680622-Tissue Distribution
|
pubmed:articleTitle |
The disposition and pharmacokinetics of alpidem, a new anxiolytic, in the rat.
|
pubmed:affiliation |
Clinical Research Department, Synthelabo Recherche, Meudon-la-Foret.
|
pubmed:publicationType |
Journal Article
|